PPAR

PPAR

pioglitazone

Manufacturer:

Medley Pharma

Distributor:

Bell-Kenz Pharma

Marketer:

Ambica
Concise Prescribing Info
Contents
Pioglitazone HCl
Indications/Uses
Type 2 DM: As monotherapy in patients inadequately controlled by diet & exercise for whom metformin is inappropriate because of contraindications or intolerance. As dual therapy in combination w/ metformin in patients w/ insufficient glycemic control despite maximal tolerated dose of monotherapy w/ metformin. As triple oral therapy in combination w/ metformin in patients w/ insufficient glycemic control despite dual oral therapy.
Dosage/Direction for Use
Initially 15-30 mg once daily increased to 45 mg once daily according to response. May be increased in increments up to 45 mg once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Active or history of cardiac failure (NYHA stages I-IV). Hepatic impairment. Pregnancy & lactation.
Special Precautions
Not to be used in patients w/ active or history of heart failure & bladder cancer. Not indicated to patient w/ NYHA class III or IV cardiac status. Fluid retention may develop & risk of hypoglycemia. Patients w/ edema. Dose-related wt gain & resumption of ovulation may occur. Decreased Hb & hematocrit. Discontinue if any deterioration in cardiac status or jaundice occurs. Liver dysfunction.
Adverse Reactions
GI disturbances, wt gain, edema, anemia, headache, visual disturbances, dizziness, arthralgia, hypoesthesia, hematuria, upper resp tract infection, sinusitis.
Drug Interactions
Increased AUC w/ CYP2C8 inhibitor eg, gemfibrozil. Decreased AUC w/ CYP2C8 inducer eg, rifampin. Inhibits metabolism w/ ketoconazole.
MIMS Class
ATC Classification
A10BG03 - pioglitazone ; Belongs to the class of thiazolidinediones. Used in the treatment of diabetes.
Presentation/Packing
Form
PPAR tab 30 mg
Packing/Price
100's;30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in